drugset / Trial / NCT02884713

Levofloxacin-Doxycycline for Helicobacter Pylori Eradication in Saudi Arabia

NCT02884713

NaSingle-groupOpen-labelTreatment

Summary

Helicobacter pylori (H. pylori) eradication is achieved in 60-80% with first-line therapy. Different second-line therapeutic options are available. However, the success of second-line therapy has not been addressed or reported from Saudi Arabia. Objectives The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment.

Timeline

Start
2013-06
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 100 mg
Subject Esomeprazole Small molecule 20 mg
Subject Levofloxacin Small molecule 500 mg

Indications